CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 20,000 target
Drug / intervention
Biopsyprocedure
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Age 18 years or older
  • ✓Solid malignant tumor or hematological malignancy
  • ✓French social security compliance per Article L.1121-11
  • ✓Voluntary signed informed consent prior to study procedures
Key exclusion· 5
  • ✕Any condition making participation undesirable or compromising protocol compliance per investigator judgment
  • ✕Under guardianship or deprived of liberty by judicial or administrative decision
  • ✕Incapable of giving consent
  • ✕Pregnant or breast-feeding women

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04932525
NCT04932525N/ARecruitingOn TrackUpdated 4mo ago
Long Recruiting
CompareCT.gov

Gustave Roussy Cancer Profiling

Gustave Roussy, Cancer Campus, Grand Paris·interventional·Posted Jun 21, 2021·Updated Feb 6, 2026

In Brief

A clinical study evaluating Biopsy for Solid Tumor, Unspecified, Adult. Currently recruiting, targeting 20,000 participants across 4 sites.

Detailed Summary

The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Unspecified, Adult
CountriesFrance
Collaborators--

Timeline

N/ARecruiting
202220232024202520262027202820292030203120322033
First PostedJun 21, 2021
Enrollment StartMay 10, 2021
Primary CompletionMay 10, 2033
TodayJul 2, 2026
Enrollment to primary: 12 yearsPosted 5.0 years agoPrimary completion in 6.9 years

Interventions

Biopsyprocedure

Blood and tumor samples for Genetic Profiling research